Engineered immune cells take on Hard-to-Treat KRAS cancers

NCT ID NCT05389514

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Providence Health & Services Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a new approach for people with advanced cancers that have a specific genetic change called KRAS G12V. Patients receive their own immune cells that have been genetically modified to recognize and attack the cancer. They also get chemotherapy and an immunotherapy drug to help the cells work. The goal is to see if this combination can shrink tumors in people who have run out of standard options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gene-engineered T cells (KRAS G12V-reactive) plus cyclophosphamide, gemcitabine, and pembrolizumab
What this could lead to: If it works, this could offer a new treatment option for people with advanced cancers that have a specific KRAS mutation, potentially shrinking tumors and extending life.
What could go wrong: This is an early, small trial with only a few participants. The treatment involves strong chemotherapy and immunotherapy, which can cause serious side effects. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS G12V MUTANT ADVANCED EPITHELIAL CANCERS

More trials for these conditions

Other studies related to the condition(s) this trial covers.